ZEGALOGUE (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Zegalogue (autoinjector), and what generic alternatives are available?
Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-three patent family members in twenty-four countries.
The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. One supplier is listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Zegalogue (autoinjector)
Zegalogue (autoinjector) will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
Indicators of Generic Entry
Summary for ZEGALOGUE (AUTOINJECTOR)
| International Patents: | 33 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | ZEGALOGUE (AUTOINJECTOR) at DailyMed |
-patent-expirations.png "ZEGALOGUE (AUTOINJECTOR) drug patent expirations")
Pharmacology for ZEGALOGUE (AUTOINJECTOR)
| Drug Class | Antihypoglycemic Agent |
| Mechanism of Action | Glucagon Receptor Agonists |
| Physiological Effect | Increased Glycogenolysis |
Anatomical Therapeutic Chemical (ATC) Classes for ZEGALOGUE (AUTOINJECTOR)
US Patents and Regulatory Information for ZEGALOGUE (AUTOINJECTOR)
ZEGALOGUE (AUTOINJECTOR) is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting ZEGALOGUE (AUTOINJECTOR)
Glucagon analogues
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting ZEGALOGUE (AUTOINJECTOR)
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEGALOGUE (AUTOINJECTOR)
See the table below for patents covering ZEGALOGUE (AUTOINJECTOR) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Philippines | 12015500115 | GLUCAGON ANALOGUES | See Plans and Pricing |
| Ukraine | 117103 | СПОЛУКА, ЯКА МАЄ АКТИВНІСТЬ АГОНІСТА ГЛЮКАГОНУ (GLUCAGON ANALOGUES) | See Plans and Pricing |
| New Zealand | 704043 | Glucagon analogues | See Plans and Pricing |
| South Korea | 20150032912 | GLUCAGON ANALOGUES | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
